Subacute Paraneoplastic Cerebellar Degeneration in an Advanced Small Cell Lung Cancer Patient: Case Report and Literature Review

• Maria Fernanda Evangelista Simões

  Núcleo de Oncologia da Bahia, Bahia, Brazil

• Clarissa Maria de Cerqueira Mathias

  Núcleo de Oncologia da Bahia, Bahia, Brazil

• Oddone Freitas Melro Braghiroli

  Núcleo de Oncologia da Bahia, Bahia, Brazil

• Eldsamira da Silva Mascarenhas Schettini Sobrinho

  Núcleo de Oncologia da Bahia, Bahia, Brazil

Introduction: Paraneoplastic Cerebellar Degeneration (PCD) is a rare paraneoplastic syndrome, and difficult to diagnose. PCD is associated with certain types of cancer such as ovarian cancer, uterus or its annexes, breast cancer, Hodgkin's lymphoma and small cell lung cancer (SCLC), however, this syndrome is not associated with metastatic dissemination. Here we report a case of a patient with advanced SCLC, which develop PCD.

Case Report: Female patient, 51-year-old, large smoker, with advanced SCLC with involvement of abdominal lymph nodes, presented muscle weakness, without spinal cord level, during second-line treatment with Cisplatin and Irinotecan, even with important clinical response to chemotherapy. The patient developed nystagmus and cerebellar ataxia. Cerebrospinal fluid analysis and brain magnetic resonance imaging without findings. The patient was assessed by neurologist, with clinical diagnosis of subacute PCD. Patient started pulse therapy with methylprednisolone, with significant remission of neurological symptoms.

Discussion and conclusion: PCD finding, although rare, usually precedes the detection of a tumor, and it is important to start early research and treatment of cancer because of better survival and patient´s quality of life. This case differs from usual descriptions found in the literature because the patient developed PCD during good clinical response in second-line treatment. PCD evolves with progression of the neurological condition in weeks to months and then stabilizes. The low incidence difficult to establish treatment strategies based on evidence for PCD, usually taking up aggressive immunotherapy, using intravenous immunoglobulin, plasmapheresis, steroids at high doses and/or immunosuppressive drugs.

Bardy FB, Cagy M, Pompeu Filho F, et al. Paraneoplastic subacute cerebellar degeneration: case report. Arq Neuropsiquiatr 2000; 58(3-A): 764-8. http://dx.doi.org/10.1590/S0004-282X2000000400029

Zhang C, Emery L, Lancaster E. Paraneoplastic Cerebellar Degeneration associated with Noncutaneous Merkel cell carcinoma. Neurol Neuroimmunol Neuroinflamm 2014; 1(2): e17. http://dx.doi.org/10.1212/NXI.0000000000000017

Candler PM, Hart PE, Barnett M, Weil R, Rees JH. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry 2004; 75(10): 1411-5. http://dx.doi.org/10.1136/jnnp.2003.025171

Hammack J, Kotanides H, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin’s disease. Neurology 1992; 42(10): 1938-43. http://dx.doi.org/10.1212/WNL.42.10.1938

Zaborowski MP, Spaczynski M, Nowak-Markwitz E, Michalak S. Paraneoplastic neurological syndromes associated with ovarian tumors. J Cancer Res Clin Oncol 2015; 141(1): 99-108. http://dx.doi.org/10.1007/s00432-014-1745-9

Graus F, Ariño H, Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood 2014; 123(21): 3230-8. http://dx.doi.org/10.1182/blood-2014-03-537506

Elomrani F, Ouziane I, Boutayeb S, Bensouda Y, Mrabti H, Errihani H. Ovarian cancer revealed by paraneoplastic cerebellar degeneration: a case report. Pan Afr Med J 2014; 18: 2. http://dx.doi.org/10.11604/pamj.2014.18.2.2808

Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal anti-bodies: analysis of 50 patients. Brain 2003; 126(6): 1409-18. http://dx.doi.org/10.1093/brain/awg133

Salgueiro AG. Editor. Síndromes paraneoplásicas neurológicas, a propósito de um caso clínico de cancro de pulmão de pequenas células

Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7(4): 327-40. http://dx.doi.org/10.1016/S1474-4422(08)70060-7

Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert–Eaton myasthenic syndrome. Brain 1997; 120(8): 1279-300. http://dx.doi.org/10.1093/brain/120.8.1279

Sabater L, Höftberger R, Boronat A, Saiz A, Dalmau J, Graus F. Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer. PLoS One 2013; 8(3): e60438. http://dx.doi.org/10.1371/journal.pone.0060438

Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2007; 2: 22. http://dx.doi.org/10.1186/1750-1172-2-22

Oliveira N, Acchar M, Prado M, Vasconcellos LF, Py MO. Ataxia and chorea related to paraneoplasic syndrome. Rev Bras Neurol 2014; 50(2): 44-7.

Milanez FM, Pereira CA, Trindade PH, Milinavicius R, Coletta EM. Lung adenocarcinoma, dermatomyositis, and Lambert-Eaton myasthenic syndrome: a rare combination. J Bras Pneumol 2008; 34(5): 333-6. http://dx.doi.org/10.1590/S1806-37132008000500014

Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. Neurol Neurosurg Psychiatry 2004; 75(8): 1135-40. http://dx.doi.org/10.1136/jnnp.2003.034447

Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006; 13(7): 682-90. http://dx.doi.org/10.1111/j.1468-1331.2006.01266.x

Greenlee JE. Treatment of paraneoplastic cerebellar degeneration. Curr Treat Options Neurol 2013; 15(2): 185-200. http://dx.doi.org/10.1007/s11940-012-0215-4

Landtblom AM, Lindvall B, Ledin T, Berlin G. A case report of plasmapheresis treatment in a patient with paraneoplastic cerebellar degeneration and high anti-yo antibody titers. Ther Apher Dial 2008; 12(1): 82-5. http://dx.doi.org/10.1111/j.1744-9987.2007.00546.x

Thöne J, Hohaus A, Lamprecht S, Bickel A, Erbguth F. Effective immunosuppressant therapy with cyclophosphamide and corticosteroids in paraneoplastic cerebellar degeneration. J Neurol Sci 2008; 272(1-2): 171-3. http://dx.doi.org/10.1016/j.jns.2008.04.020

Esposito M, Penza P, Orefice G, et al. Successful treatment of paraneoplastic cerebellar degeneration with Rituximab. J Neurooncol 2008; 86(3): 363-4. http://dx.doi.org/10.1007/s11060-007-9479-z

Abdelrahman MZ, Zeehaida M, Rahmah N, et al. Fatal septicemic shock associated with Strongyloides stercoralis infection in a patient with angioimmunoblastic T-cell lymphoma: a case report and literature review. Parasitol Int 2012; 61(3): 508-11. http://dx.doi.org/10.1016/j.parint.2012.04.005

Sliwa JA, Thatcher S, Jet J. Paraneoplastic subacute cerebellar degeneration: functional improvement and the role of rehabilitation. Arch Phys Med Rehabil 1994; 75(3): 355-7. http://dx.doi.org/10.1016/0003-9993(94)90042-6

Fu JB, Raj VS, Asher A, et al. Inpatient rehabilitation performance of patients with paraneoplastic cerebellar degeneration. Arch Phys Med Rehabil 2014; 95(12): 2496-9. http://dx.doi.org/10.1016/j.apmr.2014.07.003

Perlmutter E, Gregory PC. Rehabilitation treatment options for a patient with paraneoplastic cerebellar degeneration. Am J Phys Med Rehabil 2003; 82(2): 158-62. http://dx.doi.org/10.1097/00002060-200302000-00014

• PDF